Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment


Sientra, Inc
Human Otc Drug
NDC 71241-003
Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment is a human otc drug labeled by 'Sientra, Inc'. National Drug Code (NDC) number for Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment is 71241-003. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment drug includes Avobenzone - 3 g/100g Homosalate - 15 g/100g Meradimate - 5 g/100g Octisalate - 5 g/100g Octocrylene - 10 g/100g . The currest status of Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment drug is Active.

Drug Information:

Drug NDC: 71241-003
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Biocorneum Plus Broad Spectrum Spf 30 Advanced Scar Treatment
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Sientra, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:AVOBENZONE - 3 g/100g
HOMOSALATE - 15 g/100g
MERADIMATE - 5 g/100g
OCTISALATE - 5 g/100g
OCTOCRYLENE - 10 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 31 Mar, 2020
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 25 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Sientra, Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:G63QQF2NOX
V06SV4M95S
J9QGD60OUZ
4X49Y0596W
5A68WGF6WM
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
71241-003-961 BOTTLE, PUMP in 1 CARTON (71241-003-96) / 1 g in 1 BOTTLE, PUMP (71241-003-01)31 Mar, 2020N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose biocorneum can reduce the appearance of scars and is ideal for use on any intact skin surface, including skin that flexes (such as joints) and areas exposed to sun (such as the face and hands).

Product Elements:

Biocorneum plus broad spectrum spf 30 advanced scar treatment biocorneum plus broad spectrum spf 30 advanced scar treatment dimethicone crosspolymer (450000 mpa.s at 12% in cyclopentasiloxane) homosalate homosalate meradimate meradimate octisalate octisalate octocrylene octocrylene avobenzone avobenzone

Indications and Usage:

Directions • ensure that the affected area is clean and dry. • apply a thin, even layer twice daily. • allow to dry. wait 15 minutes before sun exposure. • children under 6 months of age: ask a doctor.

Uses biocorneum® can reduce the appearance of scars and is ideal for use on any intact skin surface, including skin that flexes (such as joints) and areas exposed to sun (such as the face and hands).

Warnings:

Warnings skin cancer/skin aging alert: spending time in the sun increases your risk of skin cancer and early skin aging. this product has been shown only to help prevent sunburn, not skin cancer or early skin aging. for external use only. do not use on damaged or broken skin. when using this product keep out of eyes. rinse with water to remove. stop use and ask a doctor if rash occurs.

Dosage and Administration:

Dosage and administration section ensure that the affected area is clean and dry. apply a thin, even layer twice daily. allow to dry. wait 15 minutes before sun exposure. children under 6 months of age: ask a doctor.

Dosage Forms and Strength:

Dosage form gel

Package Label Principal Display Panel:

Principle display section biocorneum advanced scar treatment broad spectrum spf 30 for professional use only net wt 0.35 fl oz (10g) biocorneum by sientra is the only advanced scar treatment with silishield patented crosslinked silicone plus spf 30 protection. what is silishield? silishield advances the benefits of traditional silicone sheeting through the comfort and ease of a gel. patented crosslinked silicone creates an invisible shield that feels like a second skin and helps reduce the appearance of scars. it can reduce redness and discoloration, soften and flatten new and older hypertrophic and keloid scars resulting from surgical procedures, injuries and burns. the spf is designed to be effective while also maintaining silishield’s silky-smooth feel and clear appearance. manufactured in the usa for sientra, inc., santa barbara, ca 93117 2019 sientra, inc. sientra.com biocorneum and silishield are registered trademarks of sientra, inc. may be covered by one or more of the following u.s. patents: 5,741,509; 8,021,683; 8,802,133; 9,339,546; 9,795,706 biocorneum


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.